Compare Canadian Natural Resources Ltd. (CNQ) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Canadian Natural Resources Ltd. vs Recursion Pharmaceuticals Inc — how do they compare? Canadian Natural Resources Ltd. trades at $47.79 (market cap $98.11B), while Recursion Pharmaceuticals Inc trades at $3.3 (market cap $1.81B). The key difference: Canadian Natural Resources Ltd. is far larger — about 54.2× Recursion Pharmaceuticals Inc's market cap, and Canadian Natural Resources Ltd. pays a 3.73% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| CNQ | RXRX | |
|---|---|---|
Market Cap | $98.11B | $1.81B |
Sector | Energy | Health |
52-Week High | $50.55 | $6.79 |
52-Week Low | $29.31 | $2.84 |
Enterprise Value | $108.54B | $1.33B |
Dividend Yield | 3.73% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CNQ trades at $47.25, up 3.82% in 24 hours, with a bullish technical signal and strong earnings beats in recent quarters. The company reported Q2 2026 EPS of $1.53, exceeding expectations, and maintains robust profitability with a net income margin of 22.87%. Recent news highlights record production and a quarterly dividend of $0.63, reinforcing financial strength.
Outlook is positive due to low valuation multiples, consistent dividend payouts, and upward earnings revisions. Key risks include oil price volatility and rising debt levels. Analyst consensus is strongly bullish with 75% buy ratings, supporting potential upside if operational momentum continues.
RXRX trades at $3.33, up 1.22% in the last session, with a bearish technical signal and RSI near overbought levels. The company reported a Q2 2026 earnings miss with revenue of $54M and a net loss of $519M, reflecting a net margin of -961.97%. Recent news highlights participation in investor conferences and a Genentech partnership advancement, but competitive pressures and slow revenue growth remain concerns.
Outlook is cautious due to persistent losses and high cash burn, though partnerships provide some validation. Risks include execution challenges in drug discovery and reliance on milestone payments. Analysts show a mixed stance with 40% buy ratings, but the stock faces headwinds from weak profitability and bearish technical trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Canadian Natural Resources Ltd.
Canadian Natural Resources is one of the largest oil and natural gas producers in western Canada, supplemented by operations in the North Sea and Offshore Africa. The company's portfolio includes light and medium oil, heavy oil, bitumen, synthetic oil, natural gas liquids, and natural gas. Production averaged 1.16 million barrels of oil equivalent per day in 2020, and the company estimates that it holds over 11.5 billion boe of proven and probable crude oil and natural gas reserves.
Read more on CNQ →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
